Schering-Plough Corporation, a prominent player in the pharmaceutical and biotechnology industry, is headquartered in the United States. Founded in 1851, the company has a rich history marked by significant milestones, including its merger with Merck & Co. in 2009, which expanded its global reach and product portfolio. Schering-Plough is renowned for its innovative solutions in areas such as immunology, oncology, and cardiovascular health. Its core products, including specialty pharmaceuticals and biologics, are distinguished by their commitment to improving patient outcomes through advanced research and development. With a strong market position, Schering-Plough has achieved notable recognition for its contributions to healthcare, making it a trusted name in the industry. The company continues to focus on delivering unique therapies that address unmet medical needs, solidifying its reputation as a leader in the pharmaceutical landscape.
How does Schering-Plough Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Schering-Plough Corporation's score of 69 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Schering-Plough Corporation, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is part of a corporate family that includes Merck & Co., Inc., from which it inherits its climate commitments and performance metrics. As a merged entity, Schering-Plough's climate initiatives and reduction targets are aligned with those of Merck & Co., Inc. However, specific reduction targets or achievements for Schering-Plough itself are not detailed. The company is involved in broader industry efforts to address climate change, but without specific data, it is challenging to quantify its individual impact. The emissions data and climate commitments are cascaded from Merck & Co., Inc., which is actively engaged in sustainability initiatives and has set science-based targets for emissions reductions. This relationship underscores Schering-Plough's commitment to aligning with industry standards and contributing to climate action, although specific metrics for Schering-Plough remain unspecified.
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,532,400,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Schering-Plough Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.